2017 Established the Protein and Peptide Drug Application Engineering Technology Center at the Institute of Advanced Technology, USTC.
2018 Initiated KS-V Peptide in collaboration with IAT, USTC, and Hefei High-tech Construction Investment Group.
2019 Achieved first prize in "Creative China" Hefei Innovation and Entrepreneurship Competition.
2020 Collaborated with Suzhou Innovation Institute, established Suzhou branch, and joined Suzhou Research Institute's incubation platform.
Co-founded "Peptide Drug Research and Development Center" with Shanghai Institute of Pharmacy and Suzhou Innovation Institute.
Organized the 16th Chinese International Peptide Symposium (CPS2020).
2021 Selected for Anhui Innovation and Entrepreneurship Project, established Shanghai Marketing Center.
Invited to 2021 Torch Science and Technology Achievements Direct Train (Anhui Station) and hosted the Yangtze River Delta Artificial Intelligence Innovative Drug R&D Industry Summit.
2021-2022 Completed angel round financing and round A financing.
2022 Unveiled Anhui Province Innovative Drug Concept Verification Center, established wholly-owned subsidiary KS-Changli.
2019-2022 Recognized as "Young Eagle Enterprise" for four consecutive years, National High-tech Enterprise, Hefei key enterprise, and more.
2023 Relocated KS-V Peptide to the National Big Data Health Industrial Park.